Who will prescribe testosterone to a woman?

Why it's harder than getting estrogen, what to ask for, and how the directory works.

This is the question that actually gets typed into search boxes, and it's the one with the least honest writing behind it. Most of what exists is either a clinic advertising itself or a forum thread from 2019.

I can't tell you who will prescribe for you, and I'll explain later why I won't name clinics. I can tell you how the system works, which turns out to be more useful, because once you understand why doctors hesitate you can ask better questions.

First, the thing nobody says out loud: more women are getting it

Prescribing to US women has climbed sharply. A 2026 analysis using Epic Cosmos, a database drawing on more than 300 million patient records, found testosterone prescribing to women rose 2.6-fold between 2016 and 2025, from 50.0 to 130.8 prescriptions per 100,000. Nearly a 59% jump in 2025 alone.

So you're not asking for something exotic. You're asking for something that a lot of clinicians have quietly started doing, faster every year.

(Avivi, Stuenkel, Sampath-Kumar and Ben-Yehuda, JACC: Advances, 2026.)

And the thing that paper says next, which you should hear

The same authors are cardiologists, and their point wasn't to celebrate the trend. It was to note that the safety evidence hasn't kept up.

They measured zero cardiovascular outcomes in women. There were none to measure. Everything known about testosterone and cardiovascular safety in this context is extrapolated from trials in men, principally TRAVERSE.

There was one cardiovascular trial in women, BLISS, run on the LibiGel product. It completed. It was never published.

I'm putting this on the page that's supposed to help you get a prescription because I'd rather you walk into that appointment knowing the honest state of the evidence. Prescribing is rising fast, and the long-term cardiovascular safety data in women does not exist. Both of those are true at once. A clinician who hesitates is not necessarily being obstructive.

Why it's harder than getting estrogen

Four separate frictions, and they stack.

1. It's entirely off-label. There's no FDA-approved testosterone product dosed for women in the United States. I checked the FDA's own database in July 2026: ten marketed brand-name testosterone products, none carrying a female indication. Prescribers therefore use roughly a tenth of a male product's dose, or a compounded preparation. Off-label prescribing is legal and routine, but it puts the decision entirely on the individual clinician, with no manufacturer's label to point to.

2. It's a Schedule III controlled substance. Estradiol and progesterone are ordinary prescriptions. Testosterone isn't, and hasn't been since 1990. That means DEA registration, prescription limits, and every dispensing recorded in the state prescription monitoring database. Some pharmacy chains apply extra scrutiny to off-label testosterone for women as a matter of policy.

3. Telehealth is genuinely unsettled. Tele-prescribing controlled substances has been running on temporary federal flexibilities for years. The permanent rule covering it was proposed in January 2025 and still isn't finalized. Some practices simply won't tele-prescribe testosterone, or require an in-person visit first. This is why a woman can be an established patient at an online menopause clinic, be prescribed estrogen without friction, and be told no on testosterone. It usually isn't the clinician's opinion of testosterone. It's the schedule.

4. Compounding varies. Because no female-dosed product exists, many prescriptions are compounded creams. Pharmacies differ in what they'll prepare and what they'll ship across state lines.

(Project regulatory research: research/regulatory/np-scope-and-testosterone-regulation.md. FDA counts: fda-orangebook-2026-07-testosterone-approved-products, queried 2026-07-25.)

What the professional guidelines actually authorize

This matters because it shapes what a cautious clinician believes they're permitted to do.

The 2019 global consensus statement, endorsed by eleven professional bodies including the Endocrine Society and ACOG, concluded that the only evidence-based indication for testosterone in women is hypoactive sexual desire disorder. For everything else, including fatigue, mood, cognition and bone, they found the data insufficient to recommend it.

They also said that since no approved female product exists, male formulations can be used judiciously, at doses producing concentrations in the normal premenopausal range, and that the diagnosis should come from clinical assessment rather than a blood level.

So a clinician following the guidelines to the letter has a narrow authorized indication, explicit permission to use male products at reduced doses, and instruction not to lean on your lab number. That combination explains a lot of appointments.

(Davis et al., Journal of Clinical Endocrinology and Metabolism, 2019.)

How to make the appointment go better

Not medical advice. Practical framing.

Ask about the schedule, not the drug. "Does this practice prescribe Schedule III medications, and can that be done via telehealth?" A no here is administrative, and it saves you from concluding your doctor doesn't believe you.
Know the guideline exists. Naming the 2019 global consensus statement signals you're not asking for something off the internet. It also gives a cautious clinician the cover of an endorsed document.
Don't lead with your lab result. The consensus says the level shouldn't drive the diagnosis. If you open with a number, you've handed over the easiest way to end the conversation.
Ask what monitoring they'd want. A clinician willing to prescribe usually has a monitoring plan. Asking for it reads as seriousness, and it tells you whether they've done this before.
Ask directly whether they've prescribed it to women. Experience varies enormously, and there's no polite way to find this out other than asking.

The directory, and how I'm building it

I am building a list of named clinicians. Here is the rule it runs on: nobody appears on it who hasn't said yes, in writing, with a date.

Not scraped from practice websites. Not collected from forum posts about who prescribed for someone in 2023. Not inferred from a clinic's marketing copy. I write to the clinician, tell them exactly what would be listed, and publish only if they agree.

What that means for you as a reader:

Every entry shows the date it was confirmed, so you can see how fresh it is rather than trusting that it's current.
I re-check with every listed clinician every six months. Anything not re-confirmed within nine months gets hidden rather than quietly left up to rot.
Entries say what the clinician told me about their practice. No entry claims anyone will prescribe for you specifically, because that isn't mine to promise and it isn't theirs to promise sight-unseen.
Nothing about pricing unless they volunteered it in writing, and nothing at all about any individual patient.
Any clinician can be removed the same day, by replying to me. No questions.

I researched prescribers in Colorado and watched entries go out of date within weeks. That's the real failure mode for a page like this, and it's why the dates and the re-checks matter more than the length of the list. A short, current, consented list beats a long stale one, and it isn't close.

I take no referral fees and sell nothing. If that ever changes it will be written at the top of the page in the same size type as everything else.

What I am and am not. I'm a medical technologist who reads primary research. I'm not a physician, I'm not diagnosing anyone, and none of this is a treatment recommendation. The decision belongs with a clinician who knows your history.

The six-part email series covers the rest: what testosterone does, why the trials missed it, why your labs read "normal," and the side effects nobody quantifies honestly.